Who is sponsoring NCT03980691?

NCT03980691 is sponsored by Guangzhou 8th People's Hospital.

What drugs are being tested in NCT03980691?

Interventions in NCT03980691: Chidamide with CAR-T or TCR-T cell therapy.

Is NCT03980691 still recruiting?

NCT03980691 is currently completed. Last updated 20 July 2021.

Last reviewed 2021-07-20 · How we verify

NCT03980691

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Chidamide Combined With CAT-T or TCR-T Cell Therapy on HIV-1 Latent Reservoir

Completed Phase 1 Last updated 20 July 2021

What this trial tests

Phase 1 trial testing Chidamide with CAR-T or TCR-T cell therapy in HIV/AIDS in 4 participants. Completed in 31 May 2020.

Timeline

1 December 2017

Primary endpoint
31 May 2020

31 May 2020

Quick facts

Lead sponsor	Guangzhou 8th People's Hospital
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	4
Start date	1 December 2017
Primary completion	31 May 2020
Estimated completion	31 May 2020
Sites	1 location across China

Drugs / interventions tested

Chidamide with CAR-T or TCR-T cell therapy — full drug profile →

Conditions studied

HIV/AIDS — all drugs for HIV/AIDS →

Sponsor

Guangzhou 8th People's Hospital

Who can join

Adults 18 to 60, any sex, with HIV/AIDS. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To study the safety and effectiveness of the combination of Chidamide with Chimeric Antigen Receptor(CAR)-T or T cell receptor(TCR)-T cell therapy on HIV patients based on cART.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion.
Gumber D, Wang LD. · · 2022 · cited 276× · PMID 35301179 · DOI 10.1016/j.ebiom.2022.103941
Curing HIV: Seeking to Target and Clear Persistent Infection.
Margolis DM, Archin NM, Cohen MS, Eron JJ, et al · · 2020 · cited 144× · PMID 32220311 · DOI 10.1016/j.cell.2020.03.005
Cell therapies in the clinic.
Wang LL, Janes ME, Kumbhojkar N, Kapate N, et al · · 2021 · cited 99× · PMID 34027097 · DOI 10.1002/btm2.10214
Application of CAR-T Cell Therapy beyond Oncology: Autoimmune Diseases and Viral Infections.
Zmievskaya E, Valiullina A, Ganeeva I, Petukhov A, et al · · 2021 · cited 75× · PMID 33435454 · DOI 10.3390/biomedicines9010059
Advances toward Curing HIV-1 Infection in Tissue Reservoirs.
Henderson LJ, Reoma LB, Kovacs JA, Nath A. · · 2020 · cited 52× · PMID 31694954 · DOI 10.1128/jvi.00375-19
Nose to brain delivery of antiretroviral drugs in the treatment of neuroAIDS.
Sarma A, Das MK. · · 2020 · cited 15× · PMID 34765998 · DOI 10.1186/s43556-020-00019-8
CAR-T cells leave the comfort zone: current and future applications beyond cancer.
Mazzi MT, Hajdu KL, Ribeiro PR, Bonamino MH. · · 2021 · cited 9× · PMID 36284896 · DOI 10.1093/immadv/ltaa006
Targeting the HIV reservoir: chimeric antigen receptor therapy for HIV cure.
Li S, Wang H, Guo N, Su B, et al · · 2023 · cited 8× · PMID 37927030 · DOI 10.1097/cm9.0000000000002904

Verify or expand the search:

Other recruiting trials for HIV/AIDS

Currently open trials in the same condition.

NCT06741618 — MyPEEPS Mobile Plus: A Multi-Level HIV Prevention Intervention for Young MSM · NA · recruiting
NCT07298785 — Peer-led Dynamic Choice HIV Prevention for Women: The Peer-led DCP Pilot Study · NA · recruiting
NCT07072481 — Sustaining Innovative Tools to Expand Youth-Friendly HIV Self-Testing · NA · recruiting
NCT07064785 — Video-Intervention to Inspire Treatment Adherence for Life for Adolescents · NA · recruiting
NCT07074899 — Evaluation of a Multi-Component Intervention to Support HIV Testing and Linkage to Services Among MSM in Peru · NA · active not recruiting

Other Guangzhou 8th People's Hospital trials

Trials by the same sponsor.

NCT06947356 — Comparison of TAF and TDF in Preventing Mother-to-Child Transmission of HBV in Pregnancies With High Viral Loads · NA · recruiting
NCT06137196 — Risk Identification Factors for Pulmonary Function Impairment in AIDS Patients Recovered From Severe Pneumonia · recruiting
NCT06145828 — Clinical Application of Cytokine Adsorption Technique in AIDS Patients With Severe Pneumonia and/or Septic Shock · recruiting
NCT06145841 — Metagenomic Next-Generation Sequencing Guides Anti-Infection Strategies · recruiting
NCT05988879 — Functional Cure of Hepatitis B in HIV/HBV Co-infected Patients · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03980691 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Guangzhou 8th People's Hospital
Last refreshed: 20 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03980691.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing